Key result
Resveratrol significantly decreased maximal aggregation of platelets to collagen and epinephrine in aspirin-resistant high-risk cardiac patients.
Why the study?
Does resveratrol inhibit platelet aggregation in aspirin-resistant high-risk cardiac patients?
Population
Platelet-rich plasma from aspirin-sensitive and aspirin-resistant high-risk cardiac patients
Comparison
Resveratrol (10 mol/L) in vitro vs Absence of resveratrol
Design
Preclinical
Authors
Loading...
May inhibit aggregation in ASA-resistant platelets; hypothesis-generating and should not yet change practice.
Does resveratrol inhibit platelet aggregation in aspirin-resistant high-risk cardiac patients?
Resveratrol effectively inhibits collagen- and epinephrine-induced aggregation of platelets from aspirin-resistant patients in vitro, suggesting a potential mechanism for cardioprotection.
Stef et al. (2006) studied High-risk cardiac patients with aspirin resistance. Resveratrol vs. Absence of resveratrol was evaluated on Platelet aggregation to ADP, collagen, and epinephrine. Resveratrol significantly decreased maximal aggregation of platelets to collagen and epinephrine in aspirin-resistant high-risk cardiac patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: